Key Highlights
- $4.7M funding round led by prominent investors including Phil Knight and Oregon ToughTech BreakThrough Fund.
- Ziplyft device aims to revolutionize blepharoplasty with reduced recovery times and enhanced outcomes.
- John Garland appointed as Chief Commercial Officer to drive global commercialization.
- International Society of Aesthetic Plastic Surgery reports 1.7 million eyelid surgeries in 2023.
- Accolades for Ziplyft: Eyecelerator People’s Choice Award and ASCRS Winning Pitch Challenge.
Source: Business Wire
Notable Quotes
- “This $4.7 million funding marks a pivotal moment for Osheru. It demonstrates the strong confidence in Ziplyft from both the medical community and investors, validating our vision to revolutionize blepharoplasty with cutting-edge technology.” — Dr. Patricia Buehler, CEO at Osheru
- “Joining Osheru to launch Ziplyft is an exciting opportunity. This innovative technology addresses key challenges in blepharoplasty, promising improved outcomes for patients and enhanced capabilities for surgeons. I’m eager to drive its growth and advance the field of eyelid surgery.” — John Garland, Chief Commercial Officer (CCO) at Osheru
- “Despite the challenging fundraising environment for startups today, Osheru’s success in securing this funding round highlights their perseverance and the compelling value proposition of Ziplyft.” — Skip Rung, President at ONAMI
SoHC's Take
Osheru’s successful $4.7 million funding round is a significant endorsement of their innovative approach to blepharoplasty. The Ziplyft device, with its promise of reduced recovery times and improved outcomes, stands to make a substantial impact in the field of eyelid surgery. The appointment of John Garland as Chief Commercial Officer further solidifies Osheru’s strategic direction towards effective commercialization. This funding and leadership boost positions Osheru to capitalize on the growing demand for minimally invasive cosmetic procedures, particularly as consumer interest in aesthetic enhancements continues to rise. As they move towards commercialization in 2025, Osheru is well-placed to become a leader in surgical innovation.
